AU4079999A - Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases - Google Patents

Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases Download PDF

Info

Publication number
AU4079999A
AU4079999A AU40799/99A AU4079999A AU4079999A AU 4079999 A AU4079999 A AU 4079999A AU 40799/99 A AU40799/99 A AU 40799/99A AU 4079999 A AU4079999 A AU 4079999A AU 4079999 A AU4079999 A AU 4079999A
Authority
AU
Australia
Prior art keywords
family
egfr
radiation
antibodies
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40799/99A
Other languages
English (en)
Inventor
Donald Jay Buchsbaum
Francisco Robert
Mansoor N. Saleh
Harlan W. Waksal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
ImClone LLC
Original Assignee
UAB Research Foundation
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, ImClone Systems Inc filed Critical UAB Research Foundation
Publication of AU4079999A publication Critical patent/AU4079999A/en
Priority to AU2004200705A priority Critical patent/AU2004200705A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU40799/99A 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases Abandoned AU4079999A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004200705A AU2004200705A1 (en) 1998-05-15 2004-02-23 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7961298A 1998-05-15 1998-05-15
US8561398P 1998-05-15 1998-05-15
US09079612 1998-05-15
US60085613 1998-05-15
US20613898A 1998-12-07 1998-12-07
US09206138 1998-12-07
PCT/US1999/010741 WO1999060023A1 (fr) 1998-05-15 1999-05-14 Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004200705A Division AU2004200705A1 (en) 1998-05-15 2004-02-23 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
AU4079999A true AU4079999A (en) 1999-12-06

Family

ID=27373511

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40799/99A Abandoned AU4079999A (en) 1998-05-15 1999-05-14 Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases

Country Status (14)

Country Link
EP (1) EP1080113A4 (fr)
JP (1) JP2002515511A (fr)
KR (1) KR20010071271A (fr)
CN (1) CN1314917A (fr)
AU (1) AU4079999A (fr)
BR (1) BR9910511A (fr)
CA (1) CA2332331A1 (fr)
CZ (1) CZ20004224A3 (fr)
HK (1) HK1040720A1 (fr)
IL (1) IL139707A0 (fr)
MX (1) MXPA00011248A (fr)
PL (1) PL348634A1 (fr)
SK (1) SK17282000A3 (fr)
WO (1) WO1999060023A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1745799B1 (fr) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions et méthodes pour le traitement de tumeurs
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
JP2003503313A (ja) 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
AU2002239486A1 (en) * 2000-12-08 2002-06-18 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
CA2478169C (fr) 2002-03-04 2013-04-16 Imclone Systems Incorporated Anticorps humains specifiques de kdr et leurs utilisations
ES2299692T3 (es) * 2002-04-02 2008-06-01 Nerviano Medical Sciences S.R.L. Terapia combinada contra tumores que comprende derivados de distmicina acriloil sustituido y radioterapia.
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
EP1622942B1 (fr) 2003-05-01 2014-11-19 ImClone LLC Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
CN101966338A (zh) 2003-06-09 2011-02-09 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
MXPA06001634A (es) 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
WO2005047512A2 (fr) 2003-11-12 2005-05-26 Shering Corporation Systeme de plasmide pour l'expression multigenique
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
JP4734319B2 (ja) 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
CN1968706A (zh) 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
US7811562B2 (en) 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US8128929B2 (en) 2005-06-17 2012-03-06 Imclone Llc Antibodies against PDGFRa
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
CA2625440C (fr) 2005-10-11 2023-06-13 Micromet Ag Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
NZ574580A (en) 2006-08-21 2011-12-22 Hoffmann La Roche Her2 tumor therapy with an anti-vegf antibody
SI2129396T1 (sl) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
CA2682626A1 (fr) * 2007-04-03 2008-10-09 Micromet Ag Elements de liaison bispecifiques specifiques d'especes croisees
WO2009030368A1 (fr) 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Polythérapie avec des anticorps anti-cd20 de type i et de type ii
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
EP2408479A1 (fr) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Plurithérapie contre le cancer comprenant l'administration d'un inhibiteur de l'egfr et d'un inhibiteur de l'igf-1r
ES2572728T3 (es) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
EP2236139A1 (fr) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2769595A1 (fr) 2009-08-14 2011-02-17 Roche Glycart Ag Polytherapie a base d'un anticorps afucosyle anti-cd20 et de fludarabine et/ou mitoxantrone
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2519826A2 (fr) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
EA201201186A1 (ru) 2010-03-11 2013-11-29 Мерримак Фармасьютикалс, Инк. ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
EP2563391B1 (fr) 2010-04-27 2020-08-26 Roche Glycart AG Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012080389A1 (fr) 2010-12-16 2012-06-21 Roche Glycart Ag Thérapie d'association d'un anticorps cd20 afucosylé avec un inhibiteur mdm2
EP2671082B1 (fr) 2011-02-02 2020-01-15 Amgen Inc. Méthodes et compositions associées à l'inhibition d'igf-1r
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012129145A1 (fr) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Polythérapie du cancer du poumon non à petites cellules (nsclc)
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
EP2776042B1 (fr) 2011-11-11 2019-03-20 Duke University Polythérapie médicamenteuse pour le traitement de tumeurs solides
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
JP6207531B2 (ja) * 2012-02-23 2017-10-04 ダイイチサンキョウヨーロッパ ゲーエムベーハー 放射線感受性を調節するためのｈｅｒ３阻害剤
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
JP6408993B2 (ja) 2012-09-07 2018-10-17 ジェネンテック， インコーポレイテッド タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
SI3319995T1 (sl) 2015-07-07 2019-07-31 F. Hoffmann-La Roche Ag Kombinirana terapija s konjugatom protitelo anti-HER-2 in zdravilo ter zaviralcem bcl-2
CA3006743A1 (fr) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Inhibiteurs de mat2a pour le traitement du cancer n'exprimant pas mtap
EP3405194A1 (fr) 2016-01-18 2018-11-28 Institut National de la Sante et de la Recherche Medicale (INSERM) Utilisation d'un inhibiteur temporaire de p53 à des fins de prévention ou de réduction des rechutes de cancer
WO2017205465A2 (fr) 2016-05-24 2017-11-30 Griswold Karl Edwin Anticorps et leurs procédés de production
JP2020528418A (ja) 2017-07-26 2020-09-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
CN110869391A (zh) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
TW201920282A (zh) * 2017-09-29 2019-06-01 中國大陸商上海藥明生物技術有限公司 抗egfr和pd-1的雙特異性抗體
WO2019201882A1 (fr) 2018-04-18 2019-10-24 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur de bet et un inhibiteur du protéasome
WO2020234445A1 (fr) 2019-05-23 2020-11-26 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur de bet et un inhibiteur de bcl-2
WO2021155006A1 (fr) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
WO1996040210A1 (fr) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
EP1080113A4 (fr) 2002-04-17
PL348634A1 (en) 2002-06-03
WO1999060023A1 (fr) 1999-11-25
CA2332331A1 (fr) 1999-11-25
KR20010071271A (ko) 2001-07-28
JP2002515511A (ja) 2002-05-28
EP1080113A1 (fr) 2001-03-07
MXPA00011248A (es) 2004-09-06
SK17282000A3 (sk) 2002-04-04
BR9910511A (pt) 2001-11-20
HK1040720A1 (zh) 2002-06-21
CN1314917A (zh) 2001-09-26
CZ20004224A3 (cs) 2002-02-13
IL139707A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
US20090297509A1 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AU4079999A (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
AU782994C (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
EP3954712A1 (fr) Anticorps anti-pd-l1/vegf bifonctionnel et son utilisation
KR100269879B1 (ko) 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법
KR101683884B1 (ko) 항-ＥｐＣＡＭ 항체 및 이의 용도
CN110505883A (zh) 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
US20030202973A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
KR20080110987A (ko) 항-ｅｇｆｒ 및 항-ｈｅｒ２ 항체를 이용하는 조합 요법
AU2009255305B2 (en) Monoclonal antibodies to basic fibroblast growth factor
US6733752B1 (en) Prevention of tumors with monoclonal antibodies against neu
US9358288B2 (en) Antibody combinations and use of same for treating cancer
US20150110788A1 (en) Bispecific antibodies with an fgf2 binding domain
AU2004200705A1 (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
CN114685674B (zh) 一种抗体融合蛋白及其应用
CN103374071A (zh) 一种抗derlin-1人源化抗体的制备

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted